The Role of the Gut Microbiome in Neurological Disorders

The Role of the Gut Microbiome in Neurological Disorders

---

---

 

---

---

Introduction

The human gastrointestinal tract is home to trillions of microorganisms that collectively form a highly complex and dynamic ecosystem known as the gut microbiome. This diverse community of bacteria, viruses, fungi, and archaea plays a critical role in maintaining human health by supporting digestion, regulating immune function, and influencing metabolic homeostasis. In recent years, growing scientific evidence has demonstrated that the influence of the gut microbiome extends beyond the gastrointestinal system, with significant effects on brain development, neurological function, and behavior.

Central to this emerging understanding is the concept of the gut–brain axis, a bidirectional communication network that links the gastrointestinal tract and the central nervous system. This system operates through multiple interconnected pathways, including neural signaling via the vagus nerve, endocrine mechanisms involving microbial metabolites and neuroactive compounds, and immune mediated pathways driven by cytokines and inflammatory mediators. Through these mechanisms, gut microorganisms can influence neurotransmitter synthesis, blood brain barrier integrity, neuroinflammation, and stress response pathways, all of which are relevant to neurological health and disease.

The gut microbiome is not static but evolves throughout the human lifespan. Initial microbial colonization occurs early in life and is shaped by factors such as mode of delivery, infant feeding practices, and early antibiotic exposure. During adulthood, the composition and functional capacity of the microbiome continue to be influenced by diet, medications, psychosocial stress, infections, and chronic disease states. Disruptions to this finely balanced ecosystem, commonly referred to as dysbiosis, have been increasingly associated with pathological processes both within and beyond the gastrointestinal tract.

A growing body of research now links gut microbiome dysbiosis to a range of neurological and neuropsychiatric conditions. These include neurodevelopmental disorders, neurodegenerative diseases, mood and anxiety disorders, and conditions characterized by chronic neuroinflammation. Altered microbial composition and reduced microbial diversity have been observed in patients with disorders such as Parkinson disease, Alzheimer disease, multiple sclerosis, and major depressive disorder. While causality remains an area of active investigation, mechanistic studies suggest that microbial metabolites, immune activation, and altered neural signaling may contribute to disease onset or progression.

This paper reviews the current evidence linking the gut microbiome to neurological health, with an emphasis on clinically relevant mechanisms and disease associations. It also examines emerging therapeutic strategies aimed at modulating the gut microbiome, including dietary interventions, probiotics, prebiotics, and fecal microbiota transplantation, and considers their potential role in clinical practice. By integrating insights from basic science and clinical research, this review aims to support physicians and healthcare professionals in understanding the relevance of the gut–brain axis and its implications for the diagnosis, prevention, and management of neurological disorders.

---

The Gut-Brain Axis: Mechanisms of Communication

Neural Pathways

The vagus nerve serves as the primary direct connection between the gut and brain. This cranial nerve carries signals in both directions, allowing gut bacteria to influence brain activity and vice versa. Studies show that certain bacterial strains can activate vagal pathways, affecting mood, cognition, and behavior.

Researchers have demonstrated that vagotomy (surgical cutting of the vagus nerve) can block some behavioral effects of gut bacteria in animal models. This finding supports the importance of neural communication in the gut-brain connection.

The enteric nervous system, often called the “second brain,” contains over 500 million neurons embedded in the gut wall. This network processes local information and communicates with the central nervous system through vagal and spinal pathways.

Immune and Inflammatory Pathways

Gut bacteria strongly influence immune system development and function. The intestinal barrier normally prevents harmful substances from entering systemic circulation. However, when this barrier becomes compromised (increased intestinal permeability), bacterial components can trigger inflammatory responses that affect the brain.

Pro-inflammatory cytokines such as interleukin-1 beta, tumor necrosis factor-alpha, and interleukin-6 can cross the blood-brain barrier and activate microglia, the brain’s immune cells. Chronic microglial activation contributes to neuroinflammation, which plays a role in many neurological disorders.

Conversely, beneficial bacteria produce anti-inflammatory compounds that help maintain immune balance and protect against excessive inflammation. This balance between pro- and anti-inflammatory signals influences neurological health.

Biochemical Pathways

Gut bacteria produce numerous compounds that can affect brain function. Many bacterial strains synthesize neurotransmitters identical to those produced by human neurons. For example:

Lactobacillus species produce gamma-aminobutyric acid (GABA), the brain’s primary inhibitory neurotransmitter. GABA deficiency is associated with anxiety and mood disorders.

Enterococcus and Streptococcus species produce serotonin, which regulates mood, sleep, and appetite. Approximately 90% of the body’s serotonin is produced in the gut.

Escherichia coli produces norepinephrine and dopamine, neurotransmitters involved in attention, motivation, and motor control.

Bacteria also produce short-chain fatty acids (SCFAs) through fiber fermentation. These compounds, particularly butyrate, can cross the blood-brain barrier and affect microglial activation, neurogenesis, and brain-derived neurotrophic factor expression.

 

---

Gut Microbiome Alterations in Neurological Disorders

Parkinson’s Disease

Parkinson’s disease research has revealed striking connections to gut health. Patients often experience gastrointestinal symptoms years before motor symptoms appear. Studies consistently show altered gut microbiome composition in Parkinson’s patients compared to healthy controls.

Research indicates reduced bacterial diversity and decreased levels of bacteria that produce SCFAs in Parkinson’s patients. Specific changes include reduced Prevotellaceae and increased Enterobacteriaceae family members. These alterations may contribute to increased intestinal permeability and systemic inflammation.

The protein alpha-synuclein, which forms toxic aggregates in Parkinson’s disease, appears in the enteric nervous system before reaching the brain. Some researchers propose that alpha-synuclein pathology begins in the gut and spreads to the brain through the vagus nerve, though this hypothesis requires further investigation.

Animal studies support the gut-brain connection in Parkinson’s disease. Germ-free mice (raised without gut bacteria) show reduced alpha-synuclein aggregation, while colonization with bacteria from Parkinson’s patients increases motor symptoms in these models.

Alzheimer’s Disease

Emerging evidence links gut microbiome changes to Alzheimer’s disease development and progression. Patients with Alzheimer’s disease show distinct bacterial profiles compared to cognitively healthy individuals. These changes include reduced bacterial diversity and altered ratios of beneficial to harmful bacteria.

Studies report increased levels of pro-inflammatory bacteria and decreased anti-inflammatory strains in Alzheimer’s patients. This imbalance may contribute to systemic inflammation and blood-brain barrier dysfunction, facilitating the entry of inflammatory substances into the brain.

Bacterial lipopolysaccharides, components of gram-negative bacterial cell walls, have been found in the brains of Alzheimer’s patients. These substances can trigger inflammatory responses and may contribute to amyloid plaque formation, a hallmark of Alzheimer’s disease.

Research also suggests that gut bacteria influence tau protein phosphorylation, another key feature of Alzheimer’s pathology. However, determining whether microbiome changes cause or result from the disease remains challenging.

Multiple Sclerosis

Multiple sclerosis (MS) involves complex interactions between genetic susceptibility, environmental factors, and immune dysfunction. The gut microbiome appears to play a role in this autoimmune neurological condition.

Studies consistently show altered gut bacterial composition in MS patients. Common findings include reduced bacterial diversity, decreased levels of beneficial bacteria like Faecalibacterium prausnitzii, and increased potentially pathogenic strains.

The hygiene hypothesis suggests that reduced early-life microbial exposure may contribute to autoimmune disease development. This theory partially explains the higher MS prevalence in developed countries with improved sanitation.

Molecular mimicry represents another potential mechanism linking gut bacteria to MS. Some bacterial proteins resemble human myelin proteins, potentially triggering autoimmune responses that damage the central nervous system.

Animal models of MS demonstrate that germ-free mice develop less severe disease, while colonization with specific bacterial strains can either worsen or improve symptoms depending on the species involved.

Autism Spectrum Disorders

Children with autism spectrum disorders (ASD) frequently experience gastrointestinal problems, and research reveals distinct gut microbiome patterns in this population. Studies report altered bacterial composition, often with reduced diversity and increased pathogenic bacteria.

Common microbiome changes in ASD include elevated Clostridium species, reduced Bifidobacterium levels, and altered Firmicutes to Bacteroidetes ratios. These changes may affect neurotransmitter production and inflammatory signaling.

The gut-brain connection in ASD may involve altered production of bacterial metabolites that affect behavior and cognition. Some studies suggest that certain bacterial toxins can influence neural development and function.

Gastrointestinal symptoms in ASD children often correlate with behavioral severity, supporting the connection between gut health and neurological symptoms. However, establishing causation remains difficult given the complex nature of autism.

Depression and Anxiety

Mental health disorders show clear associations with gut microbiome alterations. Patients with major depressive disorder consistently demonstrate different bacterial profiles compared to healthy individuals.

Depression-associated microbiome changes include reduced bacterial diversity, decreased levels of SCFA-producing bacteria, and altered neurotransmitter-producing bacterial strains. These changes may affect serotonin production, inflammatory signaling, and stress responses.

The hypothalamic-pituitary-adrenal (HPA) axis, which regulates stress responses, shows bidirectional interactions with the gut microbiome. Chronic stress can alter gut bacterial composition, while microbiome changes can affect HPA axis function.

Clinical studies have shown that probiotic supplementation can improve mood symptoms in some patients, though results vary and more research is needed to establish optimal treatment protocols.

---

Therapeutic Applications and Clinical Interventions

Probiotic Therapies

Probiotics represent the most extensively studied microbiome intervention for neurological disorders. These live beneficial bacteria can potentially restore healthy gut bacterial balance and improve neurological symptoms.

Clinical trials have tested various probiotic strains for neurological conditions with mixed results. Lactobacillus and Bifidobacterium species show the most promise, particularly for mood disorders and cognitive function.

For Parkinson’s disease, some studies report improved motor symptoms and quality of life with probiotic treatment. However, results vary between studies, and optimal dosing and strain selection remain unclear.

Depression and anxiety studies show more consistent positive results with certain probiotic formulations. Multi-strain probiotics often outperform single-strain products, suggesting that bacterial diversity may be important for therapeutic effects.

Challenges in probiotic therapy include strain-specific effects, individual variations in response, and the temporary nature of bacterial colonization. Most benefits disappear after discontinuing treatment, indicating the need for ongoing supplementation.

Dietary Interventions

Diet represents a powerful tool for modifying the gut microbiome and potentially improving neurological health. Specific dietary patterns can promote beneficial bacteria growth while reducing harmful strains.

The Mediterranean diet, rich in fruits, vegetables, whole grains, and olive oil, promotes beneficial bacterial growth and reduces inflammation. Studies suggest this dietary pattern may protect against cognitive decline and neurodegenerative diseases.

Fiber intake particularly influences microbiome composition by providing substrates for SCFA production. Patients with neurological disorders often benefit from increased dietary fiber, though individual tolerance varies.

Fermented foods like yogurt, kefir, sauerkraut, and kimchi provide natural sources of beneficial bacteria. Regular consumption of these foods may support gut microbiome diversity and neurological health.

Elimination diets that remove processed foods, excessive sugar, and artificial additives can help restore healthy bacterial balance. Some patients with neurological conditions show improvement with these dietary modifications.

Fecal Microbiota Transplantation

Fecal microbiota transplantation (FMT) involves transferring gut bacteria from healthy donors to patients with microbiome-related disorders. While primarily used for severe intestinal infections, research is exploring FMT for neurological conditions.

Early studies in autism spectrum disorders show some promising results, with improvements in both gastrointestinal symptoms and behavioral measures. However, these studies are small and require replication in larger populations.

Parkinson’s disease research includes case reports of symptom improvement following FMT, but controlled trials are lacking. The procedure carries risks and requires careful donor screening and patient selection.

Current FMT protocols focus on safety and standardization. Future applications for neurological disorders will require specialized protocols and long-term safety data.

Antibiotic Considerations

Healthcare professionals must consider the impact of antibiotics on the gut microbiome when treating patients with neurological disorders. Antibiotics can dramatically alter bacterial composition and potentially worsen neurological symptoms.

Some patients with neurological conditions experience symptom changes during antibiotic treatment. These effects may result from eliminating beneficial bacteria or altering bacterial metabolite production.

When antibiotics are necessary, concurrent probiotic supplementation may help preserve beneficial bacteria, though timing and strain selection require careful consideration to avoid interactions.

Post-antibiotic microbiome recovery can take months to years, emphasizing the importance of judicious antibiotic use in neurologically vulnerable patients.

---

Comparison with Traditional Treatment Approaches

Conventional Neurological Therapies

Traditional neurological treatments focus primarily on symptom management through medications that target specific neurotransmitter systems or inflammatory pathways. These approaches often provide symptom relief but may not address underlying causes.

Microbiome-based interventions offer a different approach by potentially addressing root causes of neurological dysfunction. Rather than simply blocking or enhancing specific pathways, these treatments aim to restore natural biological balance.

Conventional treatments and microbiome interventions can work together rather than competing. For example, patients taking antidepressants may benefit from additional probiotic therapy to address gut-related aspects of their condition.

The timeline for microbiome interventions differs from conventional treatments. While medications often work within hours to days, microbiome changes typically require weeks to months to show effects.

Pharmaceutical Interventions

Current psychiatric and neurological medications target specific receptors or enzymes but may have limited effects on overall brain health. Microbiome interventions potentially offer broader benefits by influencing multiple systems simultaneously.

Side effects represent another area of comparison. Pharmaceutical treatments often cause predictable side effects, while microbiome interventions generally have fewer adverse effects but more variable responses between individuals.

Cost considerations favor microbiome interventions in many cases. Dietary changes and some probiotic supplements cost less than prescription medications, though specialized treatments like FMT require substantial resources.

The evidence base for pharmaceutical treatments is generally more robust, with extensive clinical trials and regulatory approval processes. Microbiome research is rapidly expanding but still lacks the depth of traditional drug development.

---

Challenges and Limitations in Current Research

Methodological Issues

Microbiome research faces several methodological challenges that limit the interpretation of results. Standardization of sample collection, processing, and analysis remains problematic across different laboratories and studies.

Bacterial identification methods continue to evolve, with newer techniques providing more detailed information about microbial communities. However, comparing results between studies using different analytical approaches can be difficult.

Confounding variables represent another challenge in microbiome research. Factors such as diet, medications, geography, and lifestyle all influence bacterial composition and may obscure disease-related changes.

The distinction between correlation and causation remains a fundamental challenge. While many studies show associations between microbiome changes and neurological disorders, proving that bacterial alterations cause disease symptoms is more difficult.

Individual Variation

Gut microbiome composition varies dramatically between individuals, even among healthy people. This variation makes it challenging to define “normal” microbiome patterns and identify disease-specific changes.

Genetic factors influence microbiome composition, with twin studies showing heritable components of bacterial diversity. These genetic effects may interact with environmental factors to determine individual responses to interventions.

Age-related changes in the microbiome add another layer of complexity. Bacterial composition changes throughout life, potentially influencing the development and progression of age-related neurological disorders.

Cultural and geographic differences in microbiome composition may affect the generalizability of research findings. Studies conducted in one population may not apply to individuals from different backgrounds.

Clinical Translation

Translating microbiome research findings into clinical practice presents numerous challenges. The complexity of bacterial communities makes it difficult to develop standardized treatment protocols.

Regulatory pathways for microbiome-based therapies remain unclear in many jurisdictions. Traditional drug approval processes may not adequately address the unique characteristics of live bacterial treatments.

Healthcare provider education represents another barrier to clinical implementation. Many physicians lack training in microbiome science and may be unfamiliar with evidence-based microbiome interventions.

Patient acceptance and adherence to microbiome therapies can be challenging. Dietary changes require sustained behavioral modifications, while some interventions like FMT may face resistance due to their nature.

 

---

Future Research Directions

Mechanistic Studies

Future research must focus on understanding the specific mechanisms by which gut bacteria influence neurological function. Identifying the molecular pathways involved will help develop targeted therapeutic interventions.

Studies examining individual bacterial strains and their specific effects on neural function are needed. This research will help identify the most promising bacterial candidates for therapeutic development.

Animal models continue to provide valuable insights into gut-brain mechanisms. However, improved models that better reflect human physiology and microbiome composition are needed.

The role of other microorganisms beyond bacteria, including viruses, fungi, and archaea, requires investigation. These organisms may also contribute to neurological health and disease.

Clinical Trial Development

Large-scale, well-controlled clinical trials are essential for establishing the efficacy of microbiome interventions for neurological disorders. These studies must include appropriate control groups and standardized outcome measures.

Personalized medicine approaches based on individual microbiome profiles may improve treatment outcomes. Research is needed to identify biomarkers that predict treatment response.

Combination therapies that integrate microbiome interventions with conventional treatments require systematic investigation. These approaches may provide additive or synergistic benefits.

Long-term safety studies are crucial for establishing the risk-benefit profiles of microbiome interventions. Most current studies follow patients for only short periods.

Technological Advances

Advances in analytical techniques will continue to improve our understanding of microbiome function. New methods for studying bacterial metabolism and host-microbe interactions are rapidly developing.

Artificial intelligence and machine learning approaches may help identify complex patterns in microbiome data that predict disease risk or treatment response.

Development of standardized protocols for microbiome analysis will improve the comparability of research findings across different laboratories and studies.

Novel therapeutic approaches, such as engineered bacteria designed to produce specific therapeutic compounds, represent promising future directions.

---

Clinical Applications and Practice Guidelines

Patient Assessment

Healthcare professionals should consider gut health when evaluating patients with neurological disorders. A detailed history should include questions about gastrointestinal symptoms, antibiotic use, diet, and previous probiotic supplementation.

Physical examination may reveal signs of nutritional deficiencies or gastrointestinal dysfunction that could indicate microbiome imbalances. However, many microbiome-related issues may not have obvious clinical signs.

Laboratory testing for microbiome analysis is becoming more available, though clinical utility remains limited. Current tests can describe bacterial composition but may not predict treatment responses or clinical outcomes.

Collaboration with gastroenterologists or other specialists may benefit patients with both neurological and gastrointestinal symptoms. A multidisciplinary approach often provides the most effective care.

Treatment Implementation

When considering microbiome interventions, healthcare providers should start with low-risk approaches such as dietary modifications and well-studied probiotic formulations. More aggressive interventions should be reserved for severe cases.

Patient education is crucial for successful microbiome interventions. Patients must understand that effects may take time to appear and that lifestyle modifications require sustained commitment.

Monitoring patients during microbiome interventions should include both neurological and gastrointestinal symptoms. Some patients may experience temporary worsening of symptoms as their microbiome changes.

Documentation of interventions and responses helps build clinical experience and contributes to the broader understanding of microbiome therapies in practice.

Safety Considerations

Most microbiome interventions have good safety profiles, but healthcare providers should be aware of potential risks. Probiotics can cause infections in severely immunocompromised patients.

Drug interactions between probiotics and medications are generally minimal, but some antibiotics may interfere with probiotic effectiveness. Timing of administration may need adjustment.

Patients with severe gastrointestinal disorders or compromised immune systems require special consideration before starting microbiome interventions. Consultation with specialists may be appropriate.

Monitoring for adverse effects should continue throughout treatment. While serious adverse events are rare, gastrointestinal symptoms such as bloating or changes in bowel habits may occur.

---

---

Conclusion   

The relationship between the gut microbiome and neurological disorders represents a paradigm shift in understanding brain health and disease. Evidence clearly demonstrates bidirectional communication between gut bacteria and the nervous system through neural, immune, and biochemical pathways.

Research has identified distinct microbiome patterns associated with various neurological conditions, including Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, autism spectrum disorders, and mood disorders. While these associations are well-established, determining causation and developing effective interventions remains an active area of investigation.

Current therapeutic approaches show promise but require further development. Probiotic supplementation, dietary modifications, and fecal microbiota transplantation represent the primary intervention strategies, each with distinct advantages and limitations. Healthcare professionals must consider individual patient factors when selecting appropriate interventions.

The field faces several challenges, including methodological standardization, individual variation in microbiome composition, and clinical translation of research findings. However, rapid advances in analytical techniques and growing clinical interest are driving progress toward practical applications.

Future research must focus on mechanistic understanding, well-controlled clinical trials, and personalized medicine approaches. The integration of microbiome science into neurological practice will likely require updated training programs and practice guidelines.

For healthcare professionals, the gut-brain connection represents both an opportunity and a responsibility. Understanding microbiome influences on neurological health can improve patient care, but requires careful consideration of evidence quality and individual patient needs.

Key Takeaways

Healthcare professionals treating neurological disorders should recognize the importance of gut health in their patients. The gut microbiome influences brain function through multiple pathways and may contribute to the development and progression of neurological conditions.

Assessment of patients with neurological disorders should include consideration of gastrointestinal health, dietary patterns, and medication history. These factors may influence both disease progression and treatment responses.

Current evidence supports the use of dietary modifications and certain probiotic formulations as adjunctive treatments for some neurological conditions. However, healthcare providers should maintain realistic expectations about treatment effects and timelines.

The field of microbiome research is rapidly evolving, and healthcare professionals should stay informed about new developments. Clinical practice guidelines will likely evolve as more evidence becomes available.

Collaboration between neurologists, gastroenterologists, and other specialists may benefit patients with complex presentations involving both neurological and gastrointestinal symptoms.

Patient education plays a crucial role in successful microbiome interventions. Patients must understand the rationale for treatment, expected timelines for improvement, and the importance of adherence to recommended interventions.

Frequently Asked Questions:   

What is the gut-brain axis and how does it work?

The gut-brain axis is a bidirectional communication system connecting the gastrointestinal tract with the central nervous system. It operates through neural pathways (primarily the vagus nerve), immune and inflammatory signaling, and biochemical compounds produced by gut bacteria. This system allows gut microorganisms to influence brain function and behavior while the brain can also affect gut bacterial composition.

How do gut bacteria affect neurological disorders?

Gut bacteria influence neurological disorders through several mechanisms. They produce neurotransmitters like serotonin and GABA, create inflammatory or anti-inflammatory compounds, affect the integrity of both the intestinal and blood-brain barriers, and interact with the immune system. When the bacterial balance is disrupted (dysbiosis), these processes can contribute to neurological symptoms and disease progression.

Which neurological conditions are most strongly linked to gut microbiome changes?

The strongest evidence exists for Parkinson’s disease, where patients consistently show altered gut bacteria composition and often experience gastrointestinal symptoms before motor symptoms appear. Other conditions with substantial evidence include depression and anxiety disorders, autism spectrum disorders, multiple sclerosis, and Alzheimer’s disease. Research continues to explore connections with other neurological conditions.

Are probiotic supplements effective for treating neurological disorders?

Probiotic supplements show promise for certain neurological conditions, particularly mood disorders and some aspects of Parkinson’s disease. However, results vary significantly between studies and individuals. Multi-strain probiotics often perform better than single-strain products, but optimal dosing, timing, and strain selection remain unclear. Probiotics should be considered as adjunctive treatments rather than primary therapies for most neurological conditions.

How long does it take to see improvements with microbiome interventions?

Microbiome interventions typically require longer timeframes than conventional medications to show effects. Dietary changes may begin affecting bacterial composition within days to weeks, but clinical improvements in neurological symptoms often take 4-12 weeks or longer. Individual responses vary considerably, and some patients may not respond to particular interventions.

Can dietary changes alone improve neurological symptoms?

Dietary modifications can influence the gut microbiome and potentially improve neurological symptoms in some patients. The Mediterranean diet, increased fiber intake, and consumption of fermented foods show the most promise. However, dietary changes alone are rarely sufficient for managing serious neurological disorders and work best as part of a broader treatment plan.

Is fecal microbiota transplantation safe for neurological patients?

Fecal microbiota transplantation (FMT) carries risks including infection transmission and immune reactions. While some early studies show promise for conditions like autism spectrum disorders, FMT remains experimental for neurological conditions. It should only be considered in research settings or severe cases where other treatments have failed, and requires careful donor screening and patient selection.

How do antibiotics affect patients with neurological disorders?

Antibiotics can dramatically alter gut microbiome composition, potentially worsening neurological symptoms in some patients. The effects may be temporary or persist for months after treatment completion. When antibiotics are necessary, healthcare providers should consider concurrent probiotic supplementation and monitor patients for neurological changes during and after treatment.

Should all neurological patients have their gut microbiome tested?

Current microbiome testing has limited clinical utility for most neurological patients. While tests can describe bacterial composition, they cannot reliably predict disease progression or treatment responses. Testing may be helpful in research settings or for patients with concurrent gastrointestinal symptoms, but routine screening is not currently recommended.

What should patients do if they want to try microbiome interventions?

Patients interested in microbiome interventions should discuss options with their healthcare providers. Starting with low-risk approaches like dietary modifications and well-studied probiotic formulations is generally recommended. Patients should maintain realistic expectations about treatment timelines and effects, continue their prescribed medications, and report any changes in symptoms to their healthcare team.

 

---

References:  

Agirman, G., Yu, K. B., & Hsiao, E. Y. (2021). Signaling inflammation across the gut-brain axis. Science, 374(6571), 1087-1092.

Borre, Y. E., O’Keeffe, G. W., Clarke, G., Stanton, C., Dinan, T. G., & Cryan, J. F. (2014). Microbiota and neurodevelopmental windows: implications for brain disorders. Trends in Molecular Medicine, 20(9), 509-518.

Cryan, J. F., O’Riordan, K. J., Cowan, C. S., Sandhu, K. V., Bastiaanssen, T. F., Boehme, M., … & Dinan, T. G. (2019). The microbiota-gut-brain axis. Physiological Reviews, 99(4), 1877-2013.

Fung, T. C., Olson, C. A., & Hsiao, E. Y. (2017). Interactions between the microbiota, immune and nervous systems in health and disease. Nature Neuroscience, 20(2), 145-155.

Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., … & Shannon, K. M. (2015). Colonic bacterial composition in Parkinson’s disease. Movement Disorders, 30(10), 1351-1360.

Liu, S., Gao, J., Zhu, M., Liu, K., & Zhang, H. L. (2020). Gut microbiota and dysbiosis in Alzheimer’s disease: implications for pathogenesis and treatment. Molecular Neurobiology, 57(12), 5026-5043.

Lynch, S. V., & Pedersen, O. (2016). The human intestinal microbiome in health and disease. New England Journal of Medicine, 375(24), 2369-2379.

Mayer, E. A., Knight, R., Mazmanian, S. K., Cryan, J. F., & Tillisch, K. (2014). Gut microbes and the brain: paradigm shift in neuroscience. Journal of Neuroscience, 34(46), 15490-15496.

Mulak, A., & Bonaz, B. (2015). Brain-gut-microbiota axis in Parkinson’s disease. World Journal of Gastroenterology, 21(37), 10609-10620.

Rogers, G. B., Keating, D. J., Young, R. L., Wong, M. L., Licinio, J., & Wesselingh, S. (2016). From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Molecular Psychiatry, 21(6), 738-748.

Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., … & Mazmanian, S. K. (2016). Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell, 167(6), 1469-1480.

Sharon, G., Cruz, N. J., Kang, D. W., Gandal, M. J., Wang, B., Kim, Y. M., … & Mazmanian, S. K. (2019). Human gut microbiota from autism spectrum disorder promote behavioral symptoms in mice. Cell, 177(6), 1600-1618.

Tremlett, H., Bauer, K. C., Appel-Cresswell, S., Finlay, B. B., & Waubant, E. (2017). The gut microbiome in human neurological disease: a review. Annals of Neurology, 81(3), 369-382.

Vogt, N. M., Kerby, R. L., Dill-McFarland, K. A., Harding, S. J., Merluzzi, A. P., Johnson, S. C., … & Rey, F. E. (2017). Gut microbiome alterations in Alzheimer’s disease. Scientific Reports, 7(1), 13537.

Wang, Y., & Kasper, L. H. (2014). The role of microbiome in central nervous system disorders. Brain, Behavior, and Immunity, 38, 1-12.

 

 

---

[Internal Medicine -Home]

 

Video Section

Check out our extensive video library (see channel for our latest videos)

---

 

Recent Articles

• Micro-Behaviors and Macro-Mindsets: An Analysis of Subtle Human Reactions
• Burnout vs. Breakthrough: Why Some Doctors Find Joy Again After Leaving Clinical Practice
• The Truth About Physician Financial Myths: What Most Doctors Get Wrong
• Revisiting Lyme Disease Management in Primary Care
• The Psychology of Everyday Life: How Small Behaviors Reflect Deep Cognitive and Emotional Processes
• Managing ADHD in Adults: A Growing Primary Care Responsibility
• Raw Honey and Early Morning Awakening: Clinical Considerations
• Hemophilia Prophylaxis in the Era of Non-Factor Therapies
• Hidden Cognitive Decline Symptoms: What Every Internist Must Know Today
• Alternative Therapies for Depression: Breakthrough Neurostimulation Methods Show 80% Success Rate
• Pediatric Sepsis: Can Rapid Genomic Diagnostics Save Lives?
• Psychedelics for Acute Suicidality: Could the ED Become the Frontline?
• Pulse Pressure Variation: The Missing Key to Fluid Responsiveness in ED
• Screen Time, Social Media, and Teen Mental Health: What Can Family Physicians Do?
• Should Family Physicians Routinely Screen for Depression and Anxiety?
• Why Standard Blood Pressure Targets After Surgery May Be Harming Your Patients
• Evidence-Based Insights into Everyday Human Behavior
• Fascinating Psychological Insights- Evidence-Based Observations About How the Human Mind and Behavior
• Glycine’s Role in Sleep Enhancement- Clinical Evidence, Mechanisms, and Therapeutic Applications
• Early Morning Awakening Syndrome- Understanding Cortisol Dysregulation
• Why GLP-1 Non-Responders Need Earlier Anti-Obesity Medication Intervention
• Tachyphylaxis in Antidepressants: The Science Behind Treatment Resistance
• The Opioid Crisis in Family Practice: Safe Prescribing vs. Abandoning Patients
• 70 Psychology Facts That Explain How the Mind and Behavior Interact
• 100 Timeless Lessons for Growth, Success, and Happiness — With Healthcare Applications
• The Hidden Patterns of the Human Mind Evidence-Based Insights
• Asthma vs. COPD in Primary Care: Are We Missing Asthma-COPD Overlap?
• Lung Cancer Screening in Primary Care: Why Uptake Remains Low
• The Hidden Cost of Skipping Frailty Assessment: New Research Reveals
• The Spectrum of AI Influence- Comparative Impact Across Medical Specialties

   

---